Table 1 Headache incidence and characteristics after PACAP38 infusion and treatment with ketorolac and sumatriptan from 0 to 2 and 2–6 h. Headache inductions rate: number of participants who developed headache; Median peak headache: peak headache intensity recorded on a numerical rating scale from 0 to 10
From: Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache
PACAP38 infusion/treatment | 0–2 h Headache induction rate | 2–6 h Headache induction rate | 0–2 h Median Peak headache (range) | 2–6 h Median Peak headache (range) | 0–2 h Median Duration of headache (hours) | 2–6 h Median Duration of headache (hours) |
|---|---|---|---|---|---|---|
Pre-treatment Ketorolac | 16 of 17 | 13 of 17 | 1 (0–5) | 0 (0–3) | 1 | 2 |
Pre-treatment Sumatriptan | 13 of 17 | 8 of 17 | 1 (0–4) | 0 (0–5) | 0.17 | 1 |
Post-treatment Ketorolac | 16 of 17 | 12 of 17 | 1 (0–5) | 1 (0–2) | 1.17 | 4 |
Post-treatment Sumatriptan | 17 of 17 | 12 of 17 | 2 (0–7) | 1 (0–4) | 1.67 | 2 |